Biotech Investors in North America

AltamarCAM Partners is an independent, partner-led private asset manager founded in 2004 and headquartered in Madrid, Spain. The firm specializes in providing institutional investors—including insurance companies, pension funds, and financial institutions—as well as high-net-worth individuals, with access to global alternative investments across private equity, venture capital, life sciences, real assets (real estate and infrastructure), and private debt/credit. Their investment strategies encompass primaries, secondaries, and co-investments, tailored to meet diverse client needs. With over €20.8 billion in assets under management, AltamarCAM operates through a network of specialized entities, including Altamar Private Equity, Altan Capital, and Altamar Advisory Partners. These subsidiaries enable the firm to offer a comprehensive suite of services, from fund management to independent financial advisory and merchant banking. The firm's global presence includes offices in Madrid, Barcelona, Munich, Cologne, London, New York, and Santiago de Chile, supported by a team of more than 350 professionals. AltamarCAM is committed to delivering long-term value through a disciplined investment approach and a strong focus on environmental, social, and governance (ESG) principles. Their diversified portfolio and strategic partnerships, such as the recent collaboration with Mirabaud to launch an evergreen semi-liquid private equity strategy, underscore their dedication to innovation and client-centric solutions in the private markets.

Andreessen Horowitz, also known as a16z and legally AH Capital Management, LLC, is a privately held venture capital firm headquartered in Menlo Park, California. It was founded on July 6, 2009, by tech visionaries Marc Andreessen and Ben Horowitz, initially as a $300 million seed fund. From humble beginnings, it rapidly scaled to become one of Silicon Valley’s most influential VC outfits. The firm manages approximately $42 billion in assets as of May 2024—but more recent reporting points to roughly $45 billion in committed capital by April 2025. A16z’s hallmark is an operationally focused investment model: beyond funding, it offers founders access to deep networks, strategic support, talent, and infrastructure. The firm frequently structures dedicated funds across sectors like cryptocurrency, biotechnology, generative AI, gaming, and what it terms ‘American Dynamism’ (defense and industrial tech). As a stage‑agnostic investor, a16z participates in seed rounds as well as late-stage and growth financing across multiple verticals: AI infrastructure and applications, consumer platforms, fintech services, healthcare and bio tech, enterprise IT (cloud, security, SaaS), gaming, and education. The firm also recently pursued a record $20 billion megafund focused on growth‑stage AI startups in the U.S., underscoring its ambition in catalyzing emerging tech leaders.

Ascenta Capital is a Vancouver-based firm offering investor relations, strategic communications, and corporate advisory services to public companies, particularly in the small to mid-cap range. Founded in 2000, the firm helps clients in the natural resources, technology, and life sciences sectors navigate capital markets and enhance shareholder value through targeted investor outreach and messaging.Ascenta partners closely with clients to develop tailored communication strategies, including investor materials, media relations, and digital campaigns. Their deep understanding of capital markets and storytelling helps early-stage and growth companies build long-term investor support.With decades of experience in IR and capital markets, Ascenta Capital has become a trusted advisor to companies seeking to elevate their market profile. The firm maintains strong relationships with institutional and retail investor communities across Canada and the U.S.

Atlas Venture is a leading early-stage venture capital firm based in Cambridge, Massachusetts, specializing in the creation and development of biotech companies. The firm partners with scientific entrepreneurs to translate breakthrough innovations into new therapeutic solutions that address unmet medical needs. By combining deep domain expertise with an entrepreneurial approach, Atlas plays a hands-on role in company formation and growth. Since its founding, Atlas has been instrumental in launching and scaling numerous successful biotechnology startups. The firm provides more than capital—it contributes operational guidance, strategic support, and access to a robust network of advisors, co-investors, and industry leaders. This integrated approach has made Atlas a key player in the biotech ecosystem. Atlas Venture maintains a sharp focus on early-stage investing, often co-founding companies from the ground up. Its portfolio includes a broad range of therapeutic areas including oncology, immunology, neurology, and rare diseases. With its base in the biotech hub of Cambridge, the firm is well-positioned to harness cutting-edge research and talent to fuel innovation globally.

The Brain Tumor Investment Fund (BTIF) is a venture philanthropy fund and subsidiary of the National Brain Tumor Society (NBTS), leveraging over 30 years of NBTS’s expertise to support the development of innovative treatments for brain tumors. BTIF invests philanthropic capital into biotechnology, pharmaceutical, and medical device companies focused on brain tumor diagnostics and therapeutics, aiming to bridge the gap between academic discovery and commercial product development. BTIF acts as a convener and catalyst for private sector investment in the brain tumor space, fostering a robust and diverse market for drug development. The fund targets early-stage companies (pre-seed to Series A) with promising brain tumor assets, including small molecules, biologics, gene and cell therapies, vaccines, and medical devices. BTIF also provides portfolio companies with access to expert networks in neuro-oncology, regulatory affairs, and manufacturing to accelerate development. Led by a distinguished team with deep experience in brain tumor research, drug development, and investment, BTIF is headquartered in Newton, Massachusetts, USA. The fund focuses on creating new survival and quality-of-life treatment opportunities for brain tumor patients globally, investing primarily in companies based in the USA, Canada, Europe, and Israel.

Euclidean Capital, founded in 2009, serves as the single-family office managing the personal wealth of James Simons, the mathematician and founder of Renaissance Technologies. Based in New York City, the firm focuses on long-term capital preservation and growth through diversified investments in both public and private markets. It leverages a quantitative and data-driven investment philosophy inspired by Simons’s background in mathematics and hedge fund management.The firm primarily invests in sectors such as biotechnology, financial services, life sciences, and artificial intelligence, often participating in venture capital rounds from early to late stages. Euclidean Capital is known for its preference for innovative companies, especially in biotech and AI, reflecting Simons’s scientific and quantitative approach to investing. The firm operates from its headquarters in Midtown South Manhattan, New York, with a team of approximately 23 employees including investment professionals and strategists. The firm manages assets estimated in the range of $21 billion to over $700 million in disclosed securities, maintaining a portfolio that includes both public equities and private investments. It has made over 50 investments and completed 5 portfolio exits, demonstrating active engagement in venture and growth equity markets.

Foothill Ventures is an early-stage venture capital firm based in Silicon Valley, focused on backing founders building disruptive technologies across AI, biotech, and deep tech. The firm emerged following the evolution of the TEEC Angel Fund, with a continued mission to invest in bold entrepreneurs who are shaping the future through innovation. Foothill Ventures provides seed and Series A capital, along with hands-on support to help startups scale rapidly and effectively. The firm's investment thesis centers on high-potential teams solving hard technical problems with global market opportunities. Foothill Ventures actively seeks startups at the intersection of cutting-edge science and scalable business models, aiming to be a long-term partner from the earliest stages. Its team combines deep technical backgrounds with entrepreneurial experience, enabling them to add real value to their portfolio companies. While headquartered in the U.S., Foothill Ventures maintains strong ties to the Asian startup ecosystem and frequently backs globally oriented companies. With a growing portfolio and a commitment to technological advancement, the firm is positioned as a leading player in funding the next generation of transformative tech startups.

Forbion is a venture capital firm that specializes in the life sciences sector, with a particular focus on biotechnology and pharmaceuticals. Established in 2009, the firm has built a strong reputation for its investments in innovative life sciences companies. Forbion is dedicated to supporting the development of new therapeutics and technologies that can significantly impact healthcare outcomes.The firm operates primarily in Europe and North America, targeting regions that are known for their advancements in life sciences. Forbion's investment strategy emphasizes the importance of fostering innovation in healthcare, and it aims to partner with companies that are at the forefront of scientific research and development.With offices located in Amsterdam, Munich, and San Francisco, Forbion is well-positioned to leverage its extensive network and expertise in the life sciences industry. The firm is recognized for its commitment to nurturing the growth of its portfolio companies, providing not only financial support but also strategic guidance to help them navigate the complexities of the healthcare landscape.

Frazier Life Sciences is a healthcare investment firm specializing in the discovery, development, and commercialization of innovative biopharmaceuticals. The firm manages both venture and public funds, investing in private and publicly traded companies across all stages of therapeutics development. Frazier is known for its hands-on approach to company building, having formed over 30 companies since 2005 and partnering with entrepreneurs to accelerate the advancement of new therapies for patients.The firm’s venture funds primarily focus on company creation, seed, Series A, and Series B investments, while its public funds support small- and mid-cap biotech companies through IPOs, follow-ons, PIPEs, and open market financings. Frazier Life Sciences has a strong track record, with its portfolio generating over 40 FDA-approved therapeutics since 2010 and completing more than 60 IPOs or strategic acquisitions.Headquartered in Palo Alto, California, Frazier Life Sciences invests globally and maintains a diversified portfolio across therapeutic areas. The firm’s latest venture fund, Frazier Life Sciences XII, raised over $1.3 billion, underscoring its continued leadership in the biotech venture capital space. Frazier’s investments span oncology, fibrosis, rare diseases, gastrointestinal disorders, genetic diseases, neurology, immunology, infectious diseases, metabolic diseases, cardiovascular, and dermatology.

Kleiner Perkins, founded in 1972 by Eugene Kleiner and Tom Perkins, is a renowned venture capital firm based in Menlo Park, California. With a legacy of backing pioneering companies like Amazon, Google, and Genentech, the firm has been instrumental in shaping the technology landscape. Over the decades, Kleiner Perkins has invested in over 900 ventures, focusing on early-stage and growth-stage companies that drive innovation across various sectors. The firm's investment strategy encompasses a broad range of industries, including technology, healthcare, life sciences, and sustainability. Kleiner Perkins is known for its hands-on approach, partnering closely with entrepreneurs to provide not only capital but also strategic guidance and operational support. This collaborative model has led to numerous successful exits, including IPOs and acquisitions, solidifying its reputation as a top-tier venture capital firm. With offices in Menlo Park, San Francisco, and Shanghai, Kleiner Perkins maintains a global presence to support its diverse portfolio. The firm's commitment to fostering groundbreaking ideas and its track record of successful investments continue to attract visionary founders seeking to make a significant impact in their respective industries.

Lilly Asia Ventures is a prominent venture capital firm that specializes in investing in innovative healthcare companies across Asia. Founded in 2008, the firm leverages its deep industry expertise and extensive network to identify and support high-potential startups and growth-stage companies in the life sciences sector. With a strong focus on biotechnology, pharmaceuticals, and medical devices, Lilly Asia Ventures aims to drive advancements in healthcare by providing not only capital but also strategic guidance to its portfolio companies. The firm is committed to fostering innovation and improving patient outcomes through its investments. Over the years, Lilly Asia Ventures has built a diverse portfolio of companies that are at the forefront of medical research and technology. The firm prides itself on its collaborative approach, working closely with entrepreneurs and management teams to help them achieve their vision and scale their businesses effectively. As of the latest updates, Lilly Asia Ventures manages approximately $4.5 billion in assets, reflecting its strong position in the venture capital landscape. The firm is headquartered in Shanghai, China, and has a dedicated team of professionals with extensive experience in both investment and healthcare.

Medical Excellence Capital (MEC) is a New York-based early-stage venture capital firm focused on life sciences and healthcare innovation. Founded in 2020, MEC combines accomplished investment professionals and operators with a proprietary global network of physician-scientists to create a unique platform for nurturing transformative technologies in precision health. The firm specializes in company creation, seed, Series A, and Series B investments, targeting innovations that address significant unmet medical needs. MEC’s investment strategy centers on disruptive technologies such as cell therapy, gene therapy, AI/ML applied to drug discovery, synthetic biology, and regenerative medicine. The firm leverages its deep industry expertise and extensive network to accelerate the development of breakthrough therapies and diagnostics. MEC’s Scientific Advisory Board, comprised of leading innovators in regenerative medicine, gene therapy, and mitochondrial medicine, provides critical perspective and value to portfolio companies. With a team of seasoned venture capitalists, company builders, and operators, MEC supports early-stage ventures from inception through growth. The firm is closely aligned with the Medical Excellence Group, a global private health advisory network, further enhancing its ability to identify and advance high-impact opportunities in the life sciences sector.

Monograph Capital is an investment firm focused on the life sciences sector, specifically targeting companies that create new or improved therapeutics, diagnostics, and related technology-enabled business services. The firm aims to enhance healthcare outcomes through its investments. With primary offices located in London, San Francisco, and Dallas-Fort Worth, Monograph Capital bridges opportunities across North America, the United Kingdom, and Europe. This geographical presence allows the firm to leverage deep experience, relationships, and capabilities to help life sciences companies scale effectively. The Monograph team comprises individuals with decades of experience in biomedical research and clinical medicine, complemented by over 55 years of cumulative investing experience in the healthcare industry. This extensive background enables Monograph to actively contribute to the growth of nascent organizations into promising biotechnology and related life sciences businesses. Monograph Capital routinely identifies investment opportunities that have the potential to lead to transformational healthcare outcomes.

MPM BioImpact is a premier biotechnology investment firm with over 30 years of experience in company creation, venture capital, and impact investing. The firm specializes in transforming scientific discoveries into breakthrough medicines by building biotech companies from the ground up and investing across the full drug development spectrum. Leveraging a team of Entrepreneur Partners with deep expertise in research, development, clinical strategy, and commercialization, MPM BioImpact supports portfolio companies through regulatory challenges and market entry.Combining the legacy of MPM Capital's biotech venture capital track record with BioImpact's focus on patient outcomes, the firm manages over $3 billion in assets under management across early-stage venture funds, private/public impact funds, and public equities strategies. Their BIOIMPACT FUND™ approach targets companies developing therapies for serious diseases, adhering to global impact investing standards. MPM BioImpact provides strategic guidance, mentorship, and access to extensive networks of industry experts.Headquartered in Boston with a global presence, the firm invests in innovative areas like RNA medicines, oncology, cell/gene therapies, and precision medicine. Notable portfolio companies include Orna Therapeutics (circular RNA), Aktis Oncology (cancer conjugates), ElevateBio (cell/gene/RNA therapies), and NextPoint Therapeutics (precision cancer therapies).

Oncology Ventures is a New York–based venture capital firm dedicated to supporting early-stage companies at the forefront of cancer innovation. The firm’s investment strategy centers on transformative oncology startups focused on therapeutics, diagnostics, digital health, and patient-centric solutions aimed at improving outcomes and quality of life. Backed by a team of seasoned life sciences investors and oncology experts, Oncology Ventures provides more than capital — offering deep domain expertise, clinical insight, and commercialization strategy. The firm works closely with founders to navigate the complex development path in oncology, from early-stage R&D through regulatory approval and market launch. With its headquarters in New York City, Oncology Ventures targets U.S. and select international opportunities. The firm prioritizes scalable platforms, precision medicine, and disruptive models that address unmet needs in oncology care. By fostering innovation and accelerating development, Oncology Ventures aims to be a catalyst for the next generation of cancer breakthroughs.

Quadrille Capital is a Paris-based investment firm focused on technology and healthcare sectors across Europe and North America. Established in 2001, Quadrille combines fund investments, direct investments in high-growth companies, and secondary transactions to deliver a flexible and diversified investment approach. The firm partners with entrepreneurs and fund managers at the forefront of innovation and disruption. Quadrille Capital operates with a strong emphasis on growth equity, targeting companies and funds in sectors such as software, IT infrastructure, digital platforms, biotechnology, and medical technology. Its hybrid investment model allows it to allocate capital efficiently across different stages of company growth while maintaining exposure to a broad network of market leaders. The team leverages deep industry knowledge and global relationships to identify unique opportunities and create long-term value. With a proven track record and a disciplined strategy, Quadrille Capital manages institutional capital from pension funds, insurance companies, and family offices. The firm’s independent and partner-owned structure ensures alignment with its investors and portfolio companies. As technology and healthcare continue to shape the future economy, Quadrille remains focused on supporting innovation through strategic capital deployment.

Robin Hood Ventures, founded in 1999 and headquartered in Philadelphia, PA, is a prominent angel investment group dedicated to funding early-stage, high-growth startups. The firm typically invests between $250,000 and $1 million, often syndicating deals with venture capitalists, institutions, and other angel investors to maximize impact. Their investment approach combines capital infusion with strategic mentorship and operational support to help startups achieve sustained growth.With deep expertise across multiple industries—including Software, Healthcare IT, Hardtech, Life Sciences, and Consumer sectors—Robin Hood Ventures actively supports entrepreneurs beyond funding. They provide guidance on deal structuring, legal matters, and customer introductions, and often take board seats to contribute to governance and strategic direction. The firm fosters a collaborative community by connecting entrepreneurs, RHV members, and corporate partners to share knowledge and resources.Robin Hood Ventures is recognized as a key player in the Mid-Atlantic startup ecosystem, leveraging strong relationships with local innovation hubs, accelerators, universities, and government entities. Their members are experienced entrepreneurs and accredited investors who engage throughout the investment lifecycle to add value. The firm’s commitment to integrity, ambition, passion, and innovation underpins their mission to build great companies and shape the future of emerging industries.

Sofinnova Partners is recognized as one of the leading venture capital firms in Europe, particularly in the life sciences sector. Founded in 1972, the firm has a long history of successful investments in innovative healthcare companies.Sofinnova Partners primarily focuses on life sciences, including biotechnology, pharmaceuticals, and medical devices. The firm targets regions in Europe and North America, aiming to support companies that are at the forefront of medical innovation.The firm is structured to provide extensive support to its portfolio companies, leveraging a team of experienced professionals with deep industry knowledge. This team is dedicated to identifying and nurturing groundbreaking technologies that can transform healthcare.With a commitment to fostering innovation, Sofinnova Partners seeks to invest in companies that are poised to make significant impacts in their respective fields, ensuring that they are well-positioned for growth and success.

Sutter Hill Ventures is one of Silicon Valley’s original venture capital firms. Founded in 1964, it has played a formative role in the development of the region’s technology ecosystem for six decades. With approximately US$2.3 billion in assets under management, Sutter Hill focuses on early‑stage investments in enterprise software, infrastructure, cybersecurity, networking and cloud computing. The firm is known for its high‑touch approach: partners often work shoulder‑to‑shoulder with founders, sometimes serving as interim executives or helping incubate companies from the idea stage. Sutter Hill has been behind several transformative businesses, including Pure Storage, Snowflake, NetApp and Lam Research. Its network and institutional memory provide deep insight into cycles of innovation and market adoption. While headquartered in Palo Alto, the firm also maintains an office in London to engage with European entrepreneurs. Sutter Hill differentiates itself by staying invested through multiple rounds, aligning with founders’ long‑term visions and providing access to operational resources, customer introductions and recruiting support. The firm’s longevity and consistent performance have earned it a reputation as a trusted partner to some of the most ambitious technologists.

SV Health Investors is a global healthcare investment firm with a 30-year track record of transforming healthcare through strategic investments. Founded in 1993, the firm manages approximately $3.7 billion to $4.0 billion in historical commitments across diversified private equity and venture capital funds. Their investment focus spans biotechnology (including dementia), healthcare growth equity, and medical technology, supporting companies at all stages from early seed to growth and late-stage development.With offices in Boston and London, SV Health Investors leverages a team of over 50 experienced investment professionals and operating partners who bring deep sector expertise and healthcare industry experience. The firm emphasizes backing diverse entrepreneurs and management teams to build innovative healthcare companies that improve patient outcomes while generating shareholder value. To date, SV has invested in nearly 300 companies, with over 75 achieving successful IPOs or mergers and acquisitions.SV Health Investors’ portfolio includes companies across healthcare services, digital health, medical devices, and biotechnology sectors. Their hands-on approach combines capital with strategic guidance, helping portfolio companies advance novel treatments and technologies that address unmet medical needs globally. The firm is committed to fostering innovation that benefits patients and drives long-term growth in the healthcare industry.